Translating evidence into action
The Global AMR R&D Hub and ICARS are pleased to announce a new partnership that will further strengthen their efforts to translate evidence into action to mitigate antimicrobial resistance (AMR).
The collaboration will harness the power of the Global AMR R&D Hub’s Dynamic Dashboard to explore the current landscape of Operational and Implementation Research within low- and middle-income countries (LMICs), in an effort to connect AMR interventions with concrete outcomes. In doing so, the partners hope to be able to develop a pathway from knowledge to shape policy, programmes and practice.
At ICARS, we focus on Intervention and Implementation Research as a tool to tackle AMR. This deep dive into the current funding landscape of projects using such methods provides a unique opportunity to identify adaptable AMR interventions and their impact in LMICs as well as highlight research areas that would benefit from additional support, says Helle Engslund Krarup, Director of Operations at ICARS.
“We are delighted to collaborate on this project with ICARS, which enables us to leverage the knowledge base provided by the Hub’s Dynamic Dashboard to support evidence-based decision making in very concrete terms, here with a particular focus on LMICs”, says Lesley Ogilvie, Scientific Programme Officer at the Global AMR R&D Hub.
____________________________________
ICARS’ mission is to partner with low- and middle-income countries (LMICs) in their efforts to mitigate AMR. This is done by co-developing tailored solutions with LMIC governments and researchers, who then implement them on the ground using ICARS funding and expertise, building on AMR National Action Plans. ICARS was initiated by the Danish government in 2018 and is already co-developing projects in 10 countries. ICARS is currently embedded in the Danish Ministry of Health but is expected to become independent by the fall of 2021, with its own Board of Directors.
The Global AMR R&D Hub, as a knowledge centre for AMR, collects and presents information on AMR R&D investments across the One Health continuum as well as information on antibacterial products in the clinical development pipeline and market interventions. This information is intended for evidence-based decision making and enhancing collaboration and coordination for countries, foundations, organisations and initiatives to help set priorities and maximise the impact of resources invested in R&D to mitigate the AMR threat.
